bioRxivCancer BiologyPreprint
Mitochondrial sites of contact with the nucleus aid in chemotherapy evasion of glioblastoma cells
Daniela StrobbeiD, Mardja Bueno, Claudia De VitisiD, Sarah HassaniD, Danilo FaccendaiD, Krenare Bruqi, Elena Romano, Lucia PedaceiD, Andrey A. YurchenkoiD, Gurtej K. DhootiD, Ivi J Bistrot, Fábio KlamtiD, Luana Suéling LenziD, Eduardo Cremonese Filippi‐ChielaiD, Pietro Ivo D’UrsoiD, Imogen Lally, Eveline Miele, Laura FalascaiD, Sergey I. NikolaeviD, Rita ManciniiD, Federico RoncaroliiD, Guido LenziD, Michelangelo CampanellaiD
Abstract
Glioblastoma (GBM) is the most common form of a malignant primary brain tumour in adults for which therapeutic options are minimal. The rapid onset of the resistance mechanisms against the chemotherapeutic agent Temozolomide (TMZ), the first line of pharmacological care for patients, prevents the long-term validity of this approach. The underpinning biology for this remains poorly understood thus compromising the efficacy of this approach. The Translocator Protein (TSPO) is an 18kDa ubiquitous cholesterol-binding molecule on the outer membrane of mitochondria (OMM). Upregulated in cancers TSPO is required to form contacts between mitochondria and the nucleus termed: Nucleus Associated Mitochondria (NAM). In GBM tissues as well as in 2D and 3D cell cultures we assayed patterns of TSPO expression (i), autophagy/mitophagy (ii), transcription factors (iii) and susceptibility to TMZ-induced demise (iv). Confocal and ultrastructural imaging detailed the organization and redistribution of the mitochondrial network (v). Our findings show that TMZ exploits mitochondria via TSPO to aid the formation of NAM which couples the expression of the nuclear transcription factor Sterol regulatory element-binding transcription factor 1 (SREBP1) and the stabilization of YAP/TAZ. Pharmacological modulation of TSPO counteracts all the above and re-instates susceptibility to TMZ-induced demise. NAM is therefore proposed as a variable in the engagement and execution of pro-survival mechanisms in GBM thus offering a means to both insight into the pathophysiology of this disease and offer novel therapeutic strategies. Key PointsO_LITMZ exploits TSPO to curb mitochondrial quality control in glioblastoma cells. C_LIO_LITMZ-mediated MRR is associated with the relocation of mitochondria to the nucleus and modulation of transcriptional factors involved in cholesterol metabolism and adaptation to aggressive growth. C_LIO_LITSPO represents a pharmacological target to revert chemoresistance in glioblastoma cells. C_LI Importance of the StudyThis study elucidates a mitochondrion-driven mechanism of chemoresistance in human glioblastoma cells, which depends on the mitochondrial translocator protein TSPO. The administration of TSPO ligands restores susceptibility to TMZ by influencing the dynamics of transcriptional factors associated with cholesterol metabolism and mechanical transduction.
- Citations
- 2
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Heterogenous mitochondrial ultrastructure and metabolism of human glioblastoma cells: differences between stem-like and differentiated cancer cells in response to chemotherapy
Urban Bogataj, Metka Novak, … Barbara Breznik·Radiology and OncologyPeer-reviewed·Oct 27, 2025
- A multi-omics analysis of glioma chemoresistance using a hybrid microphysiological model of glioblastoma
S. Shojaei, J. Basso, … M. Akbari·bioRxiv·Oct 29, 2022
- Alterations in Cell Motility, Proliferation, and Metabolism in Novel Models of Acquired Temozolomide Resistant Glioblastoma
D. M. Tiek, J. D. Rone, … R. B. Riggins·bioRxiv·Dec 14, 2017
- BCL2L13 Influences Autophagy and Ceramide Metabolism without Affecting Temozolomide Resistance in Glioblastoma
Courtney Jessica Clark, Amir Barzegar Behrooz, … Saeid Ghavami·bioRxiv·Aug 23, 2024
- CCL20-CCR6 Signaling as a Prognostic Biomarker and Therapeutic Target in Temozolomide-Resistant Glioblastoma
Ryan J. Green, Karthick Mayilsamy, … Subhra Mohapatra·bioRxiv·Aug 27, 2026
- LNX1 Modulates Notch1 Signaling to Promote Expansion of the Glioma Stem Cell Population During Temozolomide Therapy in Glioblastoma
A. U. Ahmed·bioRxiv·Sep 10, 2020